Length of hospital stay · adults undergoing brain surgery
1 finding from 1 review
Adverse events · adults undergoing brain surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · Adolescents and adults aged over 16 years with clinical or self-assessed halitosis of oral origin; excluding induced or physiological…
The review found no eligible studies for this question.
1 finding from 1 review
VSC: methyl mercaptan · Adolescents and adults aged over 16 years with clinical or self-assessed halitosis of oral origin; excluding induced or physiological…
Hinokitiol gel showed no clear difference in VSC: methyl mercaptan compared with placebo gel; GRADE not reported.
1 finding from 1 review
Dentist-reported organoleptic test (OLT) score (scale 0 to 5) · Adolescents and adults aged over 16 years with clinical or self-assessed halitosis of oral origin; excluding induced or physiological…
It is very uncertain whether hinokitiol gel changes dentist-reported organoleptic test (OLT) score (scale 0 to 5) compared with placebo gel (very low certainty).
1 finding from 1 review
Patient-reported OLT score · Adolescents and adults aged over 16 years with clinical or self-assessed halitosis of oral origin; excluding induced or physiological…
The review found no eligible studies for this question.
1 finding from 1 review
VSC: hydrogen sulphide · Adolescents and adults aged over 16 years with clinical or self-assessed halitosis of oral origin; excluding induced or physiological…
Hinokitiol gel showed no clear difference in VSC: hydrogen sulphide compared with placebo gel; GRADE not reported.
1 finding from 1 review
Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Keratinocyte GF led to lower oral mucositis (moderate to severe) compared with placebo; GRADE not reported.
1 finding from 1 review
RR 0.74 [0.62, 0.89]
7 studies
GRADE not reported
Oral mucositis (severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Keratinocyte GF may leads to lower oral mucositis (severe) compared with placebo (low certainty).
1 finding from 1 review
Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Keratinocyte GF may leads to lower oral mucositis (any severity) compared with placebo (low certainty).
1 finding from 1 review
Exacerbations · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
1 finding from 1 review
Response rate ‐ treatment failure · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
Fluoroquinolones may leads to lower response rate ‐ treatment failure compared with amoxicillin (low certainty).
1 finding from 1 review
Response rate ‐ microbiological response · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
Fluoroquinolones may leads to higher response rate ‐ microbiological response compared with amoxicillin (low certainty).
1 finding from 1 review
Response rate ‐ improvement in sputum purulence (excellent) · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
It is very uncertain whether fluoroquinolones changes response rate ‐ improvement in sputum purulence (excellent) compared with amoxicillin (very low certainty).
1 finding from 1 review
Deaths · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
1 finding from 1 review
Quality of life · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Other adverse events clinical criteria · patients with Shigella dysentery
It is very uncertain whether fluoroquinolones changes other adverse events clinical criteria compared with beta‐lactams (very low certainty).
1 finding from 1 review
Diarrhoea · patients with Shigella dysentery
It is very uncertain whether fluoroquinolones changes diarrhoea on compared with macrolides (very low certainty).
1 finding from 1 review
Relapse ‐ not reported · patients with Shigella dysentery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found